|Mr. Scott Raymond Ward M.S., MS, B.Sc.||Chairman, Pres & CEO||1.6M||N/A||1960|
|Mr. Jeffrey S. Points||Chief Financial Officer||562.92k||N/A||1977|
|Ms. Rhonda J. Robb||Chief Operating Officer||955.89k||N/A||1968|
|Mr. Alexander Rosenstein||Gen. Counsel & Corp. Sec.||554.43k||N/A||1972|
|Ms. Sandra M. Sedo||Chief Compliance Officer||446.5k||N/A||1964|
Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary OAS, a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company was founded in 1989 and is headquartered in St. Paul, Minnesota.
Cardiovascular Systems, Inc.’s ISS governance QualityScore as of 7 December 2019 is 3. The pillar scores are Audit: 2; Board: 2; Shareholder rights: 6; Compensation: 1.